NCT05420636 2025-07-30
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
Fox Chase Cancer Center
Phase 2 Terminated
Clinical Trials
10 trialsNCT05800587 2025-04-04
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Phase 2 Recruiting
NCT02551432 2020-02-10
MISP-MK3475
Seoul National University Hospital
Phase 2 Completed
NCT00617409 2019-11-08
To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00454324 2017-07-11
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT00003281 2016-07-13
Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00006374 2014-01-15
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01079481 2013-05-30
Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer
Samsung Medical Center
Phase 1 Completed
NCT00005032 2013-02-11
Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
University of Chicago
Phase 1/2 Completed
NCT00317200 2011-05-02
A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Completed